QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cheng, A. Y. Articles by Fantus, I G. Search for Related Content PubMed PubMed Citation Articles by Cheng, A. Y. Articles by Fantus, I G.

Thiazolidinedione-Induced Congestive Heart Failure

Lecturer, Department of Medicine, Division of Endocrinology and Metabolism, University of Toronto; St. Michael's Hospital, Toronto, Ontario, Canada

I George Fantus, MD FRCPC

Professor, Department of Medicine; Director, Division of Endocrinology and Metabolism, University of Toronto; Mount Sinai Hospital and University Health Network, Toronto

Reprints: Alice YY Cheng MD FRCPC, Department of Medicine, Division of Endocrinology and Metabolism, University of Toronto, 61 Queen St. E., No. 7-015, Toronto, Ontario M5C 2T2, Canada, fax 416/867-3696, chenga{at}smh.toronto.on.ca

OBJECTIVE: To report 2 cases of thiazolidinedione (TZD)-associated congestive heart failure (CHF). As of March 13, 2004, one of the cases may represent the first description of TZD-associated cardiomyopathy in humans.

CASE SUMMARIES: A 57-year-old obese white man with type 2 diabetes was treated with pioglitazone 30 mg/day and insulin. He had no prior history of CHF and had an excellent exercise tolerance. Over the first 4 weeks of pioglitazone therapy, the patient experienced significant weight gain and subsequently developed CHF and pulmonary edema. A 50-year-old obese white man with type 2 diabetes presented with cardiogenic shock. Rosiglitazone 4 mg once daily had been initiated 6 weeks prior to presentation. He had no prior history of cardiac disease, and investigations did not reveal a cause for the cardiogenic shock. Rosiglitazone therapy was discontinued on admission. He improved and was discharged 21 days later.

DISCUSSION: TZDs are oral agents used for the treatment of type 2 diabetes. TZD-associated CHF and pulmonary edema have been reported in patients with a prior history of CHF. These 2 cases highlight that this adverse event can occur even in the absence of any preexisting history of clinical heart failure or cardiac disease. The second case may represent the first description of TZD-associated cardiomyopathy in humans. In both cases, an objective causality assessment using the Naranjo probability scale revealed that the adverse drug reaction between cardiomyopathy and rosiglitazone in this patient was probable.

CONCLUSIONS: TZD should be considered as a cause in the differential diagnosis of CHF and pulmonary edema in patients without a prior history of clinical CHF or cardiac disease. Healthcare professionals should be aware of the possible association between TZDs and cardiomyopathy.

Key Words: cardiomyopathy, congestive heart failure, thiazolidinedione

Published Online, March 23, 2004. www.theannals.com, DOI 10.1345/aph.1D400

This article has been cited by other articles:

				S. Singh, Y. K. Loke, and C. D. Furberg Thiazolidinediones and Heart Failure: A teleo-analysis Diabetes Care, August 1, 2007; 30(8): 2148 - 2153. [Abstract] [Full Text] [PDF]

				H. J. Dargie, P. R. Hildebrandt, G. A.J. Riegger, J. J.V. McMurray, S. O. McMorn, J. N. Roberts, A. Zambanini, and J. P.H. Wilding A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1696 - 1704. [Abstract] [Full Text] [PDF]

				N. Kennie, T. Antoniou, and P. Berger Elevated Creatine Kinase and Myalgia in a Patient Taking Rosiglitazone Ann. Pharmacother., March 1, 2007; 41(3): 521 - 524. [Abstract] [Full Text] [PDF]

				N. Cekmen, M. Cesur, R. Cetinbas, P. Bedel, and O. Erdemli Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus. J Intensive Care Med, January 1, 2006; 21(1): 47 - 50. [Abstract] [PDF]

				G. Boden and M. Laakso Lipids and Glucose in Type 2 Diabetes: What is the cause and effect? Diabetes Care, September 1, 2004; 27(9): 2253 - 2259. [Full Text] [PDF]